68
Participants
Start Date
May 31, 2006
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
Zevalin
"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m\^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
Research Site, Mesa
Research Site, Phoenix
Research Site, Scottsdale
Research site, Bakersfield
Research Site, Berkeley
Research Site, Beverly Hills
Research Site, Burbank
Research Site, Duarte
Research site, Los Angeles
Research site, Newport Beach
Research Site, San Diego
Research site, Vallejo
Research site, Aurora
Research site, Newark
Research site, St. Petersburg
Research Site, Coeur d'Alene
Research site, Chicago
Research site, Joliet
Research Site, Morris
Research site, Overland Park
Research Site, Shreveport
Research site, Baltimore
Research site, Boston
Research site, Detroit
Research Site, Rochester
Research Site, Saint Louis Park
Research Site, Commack
Research Site, East Setauket
Research Site, Durham
Research Site, Philadelphia
Research Site, Aberdeen
Research Site, Dallas
Research Site, Houston
Research Site, Norfolk
Research Site, Graz
Research Site, Innsbruck
Research Site, Bruges
Research Site, Ghent
Research Site, Leuven
Research Site, Edmonton
Research Site, Ottawa
Research Site, Toronto
Research Site, Montreal
Research Site, Helsinki
Research Site, Oulu
Research Site, Créteil
Research Site, Dijon
Research Site, Lille
Research Site, Limoges
Research Site, Cedax, Lyon
Research Site, Paris
Research Site, Toulouse
Research Site, Chemnitz
Research Site, Jena
Research Site, Karlsruhe
Research Site, Mainz
Research Site, Rostock
Research Site, Würzburg
Research Site, Budapest
Research Site, Debrecen
Research Site, Szeged
Research Site, Dublin
Research Site, Galway
Research Site, Bologna
Research Site, Milan
Research Site, Perugia
Research Site, Pisa
Research Site, Torino
Research Site, Gdansk
Research Site, Krakow
Research Site, Poznan
Research Site, Warsaw
Research Site, Coimbra
Research Site, Lisbon
Research Site, Porto
Research Site, Singapore
Research Site, Yonsei, Seoul
Research Site, Seoul
Research Site, Madrid
Research Site, Pamplona
Research Site, Salamanca
Research Site, Seville
Research Site, Malmo
Research Site, Uddevalla
Research Site, Umeå
Research Site, Bern
Research Site, Sankt Gallen
Research Site, Bangkok
Research Site, Leicester
Research Site, London
Collaborators (1)
Bayer
INDUSTRY
Spectrum Pharmaceuticals, Inc
INDUSTRY